Literature DB >> 33833512

Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment.

Xiao Liang1, Yudi Wang1, Hui Shi1, Mengmeng Dong1, Haobo Han1, Quanshun Li1.   

Abstract

BACKGROUND: Multidrug resistance (MDR) has emerged to be a major hindrance in cancer therapy, which contributes to the reduced sensitivity of cancer cells toward chemotherapeutic drugs mainly owing to the over-expression of drug efflux transporters. The combination of gene therapy and chemotherapy has been considered as a potential approach to improve the anti-cancer efficacy by reversing the MDR effect.
MATERIALS AND METHODS: The AS1411 aptamer-functionalized micelles were constructed through an emulsion/solvent evaporation strategy for the simultaneous co-delivery of doxorubicin and miR-519c. The therapeutic efficacy and related mechanism of micelles were explored based on the in vitro and in vivo active targeting ability and the suppression of MDR, using hepatocellular carcinoma cell line HepG2 as a model.
RESULTS: The micelle was demonstrated to possess favorable cellular uptake and tumor penetration ability by specifically recognizing the nucleolin in an AS1411 aptamer-dependent manner. Further, the intracellular accumulation of doxorubicin was significantly improved due to the suppression of ABCG2-mediated drug efflux by miR-519c, resulting in the efficient inhibition of tumor growth.
CONCLUSION: The micelle-mediated co-delivery of doxorubicin and miR-519c provided a promising strategy to obtain ideal anti-cancer efficacy through the active targeting function and the reversion of MDR.
© 2021 Liang et al.

Entities:  

Keywords:  aptamer; micelle; multidrug resistance; nucleolin; tumor targeting

Mesh:

Substances:

Year:  2021        PMID: 33833512      PMCID: PMC8019667          DOI: 10.2147/IJN.S304526

Source DB:  PubMed          Journal:  Int J Nanomedicine        ISSN: 1176-9114


  60 in total

1.  Chitosan mediated solid lipid nanoparticles for enhanced liver delivery of zedoary turmeric oil in vivo.

Authors:  Bo Yang; Jiaqi Jiang; Lei Jiang; Peiyu Zheng; Fuling Wang; Yang Zhou; Zhong Chen; Minghui Li; Mingming Lian; Shukun Tang; Xiaoying Liu; Haisheng Peng; Qun Wang
Journal:  Int J Biol Macromol       Date:  2020-01-24       Impact factor: 6.953

2.  Risk scores for hepatocellular carcinoma in chronic hepatitis B.

Authors:  Morris Sherman; Ray W Kim; James Dziura
Journal:  Hepatology       Date:  2015-03-25       Impact factor: 17.425

Review 3.  Aptamer-guided nanomedicines for anticancer drug delivery.

Authors:  Walhan Alshaer; Hervé Hillaireau; Elias Fattal
Journal:  Adv Drug Deliv Rev       Date:  2018-09-27       Impact factor: 15.470

4.  Intestinal organoids containing poly(lactic-co-glycolic acid) nanoparticles for the treatment of inflammatory bowel diseases.

Authors:  Zahra Davoudi; Nathan Peroutka-Bigus; Bryan Bellaire; Michael Wannemuehler; Terrence A Barrett; Balaji Narasimhan; Qun Wang
Journal:  J Biomed Mater Res A       Date:  2017-12-21       Impact factor: 4.396

5.  An injectable hydrogel using an immunomodulating gelator for amplified tumor immunotherapy by blocking the arginase pathway.

Authors:  Xiaomeng Ren; Ningning Wang; Yaxin Zhou; Aixin Song; Guoxia Jin; Zhonghao Li; Yuxia Luan
Journal:  Acta Biomater       Date:  2021-01-30       Impact factor: 8.947

6.  Characteristics and cytotoxicity of folate-modified curcumin-loaded PLA-PEG micellar nano systems with various PLA:PEG ratios.

Authors:  Quoc Thong Phan; Mai Huong Le; Thi Thu Huong Le; Thi Hong Ha Tran; Phuc Nguyen Xuan; Phuong Thu Ha
Journal:  Int J Pharm       Date:  2016-05-03       Impact factor: 5.875

7.  Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.

Authors:  Kenneth K W To; W W Leung; Simon S M Ng
Journal:  Exp Cell Res       Date:  2015-09-18       Impact factor: 3.905

Review 8.  Targeted and Immune-Based Therapies for Hepatocellular Carcinoma.

Authors:  Tim F Greten; Chunwei Walter Lai; Guangfu Li; Kevin F Staveley-O'Carroll
Journal:  Gastroenterology       Date:  2018-10-01       Impact factor: 22.682

9.  ABCG2 transports anticancer drugs via a closed-to-open switch.

Authors:  Benjamin J Orlando; Maofu Liao
Journal:  Nat Commun       Date:  2020-05-08       Impact factor: 14.919

10.  The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.

Authors:  Lei Zhang; Yidong Li; Qianchao Wang; Zhuo Chen; Xiaoyun Li; Zhuoxun Wu; Chaohua Hu; Dan Liao; Wei Zhang; Zhe-Sheng Chen
Journal:  Mol Cancer       Date:  2020-01-17       Impact factor: 27.401

View more
  2 in total

1.  A peptide-DNA hybrid bio-nanomicelle and its application for detection of caspase-3 activity.

Authors:  Fan Zhang; Changqing Mao; Siyu Cao; Runchi Zhang; Yi Guo; Guifang Chen; Chang Feng
Journal:  Front Chem       Date:  2022-09-06       Impact factor: 5.545

Review 2.  Broad-Spectrum Theranostics and Biomedical Application of Functionalized Nanomaterials.

Authors:  Meshal Alshamrani
Journal:  Polymers (Basel)       Date:  2022-03-17       Impact factor: 4.329

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.